5,265 views
Novo Nordisk is facing an exciting time, as investors await the acquisition of Catalent and data from Novo's obesity drug CagriSema. Also hear about Nykredit's acquisition of Spar Nord, new data from Genmab, interest rate cuts, tax sales and much more in episode 252 of the Investment Podcast. 00:00 - Intro 00:51 - Novo Nordisk 05:41 - Interest rate cuts continue 09:26 - Nykredit buys Spar Nord 16:14 - Genmab data 21:18 - Tax sales